$500m Alzheimer's drug scandal: NY scientist behind NIH-funded therapy busted for allegedly manipulating data in 20 research papers - now there are calls for trials to be cut off

Title: $500m Alzheimer's drug scandal: NY scientist behind NIH-funded therapy busted for allegedly manipulating data in 20 research papers - now there are calls for trials to be cut off

Article Snip: "...Scientists are calling for stage 3 clinical trials of an Alzheimer's drug to be scrapped after a report highlighted serious doubts about the legitimacy of research that helped the medicine reach that stage. A long-awaited report by the City University of New York (CUNY) accused one of its faculty members, neuroscientist Hoau-Yan Wang, of egregious misconduct concerning 20 research papers — defined as workplace behavior so outrageous, dangerous, or illegal that an employer cannot reasonably expect to correct it through progressive discipline. ..."

Reference: www.dailymail.co.uk

---

---

FDA fully approves 'novel' Alzheimer’s disease drug Leqembi, will be covered by Medicare

Title: FDA fully approves 'novel' Alzheimer’s disease drug Leqembi, will be covered by Medicare

Article Snip: "Leqembi has shown clinical benefit in fighting Alzheimer's disease. ...The Food and Drug Administration (FDA) has fully approved a "novel" drug used to treat adult patients with Alzheimer’s, the agency announced. Leqembi, which is produced by Japanese drugmaker Eisai and American-based drugmaker Biogen..."

Reference: www.foxnews.com
Leqembi,Medicare,Alzheimer's, Health,Alzheimer’s Drugs,Food and Drug Administration (FDA),amyloid beta-directed antibody, Biogen, Eisai, Lecanemab,

---

---

Medicare will continue to restrict coverage of a new class of Alzheimer’s drugs, even when fully approved by the Food and Drug Administration (FDA)

Title: Medicare won’t change coverage policy for pricey Alzheimer’s drugs

Article Snip: "Currently, Medicare coverage is even stricter, as the agency will only pay for the drugs if a patient receives them through a clinical trial. The treatments in question are monoclonal antibody infusions that target brain plaque known as amyloid that’s a signature characteristic of Alzheimer’s disease. The drugs are intended for early stage Alzheimer’s patients and are meant to slow the progression of memory loss, but are not a cure. They are costly, and there are only two: Eisai’s Leqembi and Biogen’s Aduhelm. Both were granted accelerated approval by FDA..."

Reference: www.yahoo.com
Centers for Medicare and Medicaid Services (CMS)

---

---